196 related articles for article (PubMed ID: 38035476)
21. The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Nguyen-Khac F; Bidet A; Troadec MB; Veronese L; Auger N; Daudignon A; Nadal N; Penther D; Michaux L; Lafage-Pochitaloff M; Lefebvre C
Leukemia; 2023 Apr; 37(4):946-947. PubMed ID: 36707618
[No Abstract] [Full Text] [Related]
22. Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.
Siebert R; Schuh A; Ott G; Cree IA; Du MQ; Ferry J; Hochhaus A; Naresh KN; Solary E; Khoury JD
Leukemia; 2023 May; 37(5):1170-1172. PubMed ID: 36973349
[No Abstract] [Full Text] [Related]
23. Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Cuccuini W; Collonge-Rame MA; Auger N; Douet-Guilbert N; Coster L; Lafage-Pochitaloff M
Curr Res Transl Med; 2023; 71(4):103423. PubMed ID: 38016422
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Lefebvre C; Callet-Bauchu E; Chapiro E; Nadal N; Penther D; Poirel HA
Ann Biol Clin (Paris); 2016 Oct; 74(5):568-587. PubMed ID: 27707672
[TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol; 2022 Jun; 115(6):762-777. PubMed ID: 35534749
[TBL] [Abstract][Full Text] [Related]
26. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
[TBL] [Abstract][Full Text] [Related]
27. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
28. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
30. [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary].
Kosztolányi S; Horváth B; Hosnyánszki D; Kereskai L; Sziládi E; Jáksó P; Alizadeh H; Szuhai K; Alpár D; Kajtár B
Orv Hetil; 2019 Jun; 160(24):944-951. PubMed ID: 31433233
[TBL] [Abstract][Full Text] [Related]
31. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
32. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
33. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
34. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
[TBL] [Abstract][Full Text] [Related]
36. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH).
Dastugue N; Lafage-Pochitaloff M; Pagès MP; Radford I; Bastard C; Talmant P; Mozziconacci MJ; Léonard C; Bilhou-Nabéra C; Cabrol C; Capodano AM; Cornillet-Lefebvre P; Lessard M; Mugneret F; Pérot C; Taviaux S; Fenneteaux O; Duchayne E; Berger R;
Blood; 2002 Jul; 100(2):618-26. PubMed ID: 12091356
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
38. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
39. [The significance and current diagnostic options of cytogenetic changes in multiple myeloma].
Kuglík P; Filková H; Oltová A; Hájek R
Vnitr Lek; 2006 Nov; 52 Suppl 2():76-8. PubMed ID: 18175433
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
